Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,738 stopped studies mapped to Lymphoma and descendants · 89% state a reason
Over the 1,738 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT04500548 | Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in… | Phase 1 | withdrawn | Aug 5, 2020 | National Cancer Institute (NCI) | Inadequate accrual rate | Enrollment / accrual |
| NCT05025423 | Phase II Trial of Venetoclax and Rituximab as Initial Therapy in Older Patients With… | Phase 2 | terminated | Aug 27, 2021 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | The study sponsor withdrew funding early, forcing this study to stop all activity and close… | Funding |
| NCT06348147 | Dara-RVd Induction for Newly Diagnosed Multiple Myeloma With Autologous Stem Cell… | Phase 2 | withdrawn | Apr 4, 2024 | UNC Lineberger Comprehensive Cancer Center | budget | Funding |
| NCT05824689 | Fluoroquinolone Resistance Prevalence Study(FRE) | — | terminated | Apr 21, 2023 | Hackensack Meridian Health | Discontinued Recruitment | Enrollment / accrual |
| NCT04758650 | Study of 68GaNOTA-Anti-MMR-VHH2 in Oncological Lesions, Cardiovascular Atherosclerosis,…(MITRAS) | Phase 2 | terminated | Feb 17, 2021 | Universitair Ziekenhuis Brussel | Delay in recruitment | Enrollment / accrual |
| NCT05515406 | A Study to Investigate the Safety, Tolerability, PK, PD, and Efficacy of ONO-7018 in… | Phase 1 | terminated | Aug 25, 2022 | Ono Pharmaceutical Co., Ltd. | The study was terminated due to a strategic decision to discontinue development. | Sponsor / business decision |
| NCT03946332 | Physical Activity for Myeloma Autograft Longitudinal Study(PAMAL) | N/A | terminated | May 10, 2019 | Centre Hospitalier Universitaire, Amiens | The study has stopped after the investigator's decision. The latter desires to analyse the… | Investigator |
| NCT07195617 | Clinical Study on Evaluating the Safety and Effectiveness of BCMA-GPRC5D CAR-T in…(r/r MM) | N/A | withdrawn | Sep 26, 2025 | Guangzhou Bio-gene Technology Co., Ltd | Due to corporate strategic adjustment. | Sponsor / business decision |
| NCT01135329 | Reduced-intensity, Related-donor Bone Marrow Transplantation Followed by High-dose… | Phase 2 | terminated | Jun 2, 2010 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | The stopping rule was met and hence the study was closed | Other (stated, no rule matched) |
| NCT01421927 | Lenalidomide After Reduced-intensity Allogeneic Stem Cell Transplantation for Relapsed…(REVALLO) | Phase 1 | terminated | Aug 23, 2011 | University Hospital, Bordeaux | target number of inclusion not reached | Other (stated, no rule matched) |
| NCT01962636 | Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for… | N/A | terminated | Oct 14, 2013 | Masonic Cancer Center, University of Minnesota | No longer a research question to answer. | Other (stated, no rule matched) |
| NCT04824794 | GEN3014 Trial in Relapsed or Refractory Hematologic Malignancies | Phase 1 / Phase 2 | terminated | Apr 1, 2021 | Genmab | The sponsor has decided to discontinue further development of GEN3014 after a comprehensive review… | Sponsor / business decision |
| NCT02943642 | Safety and Effectiveness of A-dmDT390-bisFv(UCHT1) Fusion Protein in Subjects With…(Resimmune®) | Phase 2 | withdrawn | Oct 25, 2016 | Virogen Biotechnology Inc. | This record is an earlier version (crossover design). After FDA-approved IND sponsor transfer to… | Other (stated, no rule matched) |
| NCT07082270 | Selvigaltin With Standard of Care Treatment for the Treatment of Relapsed/Refractory… | Phase 1 | withdrawn | Jul 24, 2025 | Roswell Park Cancer Institute | Sponsor withdrawal of supplying investigational drug | Other (stated, no rule matched) |
| NCT03246906 | Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity… | Phase 2 | terminated | Aug 11, 2017 | Fred Hutchinson Cancer Center | Study was terminated prior to enrolling protocol target accrual goal due to declining accrual and… | Safety / toxicity |
| NCT03757221 | Ixazomib -Daratumumab Without Dexamethasone (IDara) in Elderly Relapse Refractory…(IDARA) | Phase 2 | terminated | Nov 28, 2018 | University Hospital, Caen | Early termination (regarding the follow-up of the patients). The required sample size was reached,… | Other (stated, no rule matched) |
| NCT04955808 | Biospecimen Collection in Identifying Genetic Changes in Patients With Breast, Prostate,… | — | suspended | Jul 9, 2021 | National Cancer Institute (NCI) | Due to slow accrual on this trial, we will allow sites time to work on close-out procedures and… | Enrollment / accrual |
| NCT06698744 | UF-KURE-BCMA CAR-T Cells in Patients With Relapsed or Refractory Multiple Myeloma | Phase 1 | withdrawn | Nov 21, 2024 | David Wald | Replaced by study by different sponsor | Other (stated, no rule matched) |
| NCT06870487 | A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced… | Phase 1 | terminated | Mar 11, 2025 | Pfizer | The trial was terminated for strategic business reasons; the decision was not based on any safety… | Safety / toxicity |
| NCT06663046 | Universal CAR-T Cells (REVO-UWD-00B) for Refractory and Relapsed Multiple Myeloma | Early Phase 1 | suspended | Oct 29, 2024 | Wondercel Biotech (ShenZhen) | Because the implementation of the new regulation policy by the Chinese authority | Other (stated, no rule matched) |
| NCT03547700 | Study of Ixazomib and Romidepsin in Peripheral T-cell Lymphoma (PTCL) | Phase 1 / Phase 2 | terminated | Jun 6, 2018 | University of Michigan Rogel Cancer Center | Lack of accrual | Enrollment / accrual |
| NCT04331119 | Duvelisib Maintenance After Autologous Stem Cell Transplant in T-Cell Lymphomas | Phase 2 | terminated | Apr 2, 2020 | Washington University School of Medicine | Loss of funding | Funding |
| NCT05050461 | Immune Response After SARS-CoV-2 (COVID-19) Vaccination in a Context of Non-Hodgkin…(LYMPHO-CoVac) | N/A | terminated | Sep 20, 2021 | Versailles Hospital | Given the evolution of Covid 19, patient inclusions became very difficult or even non-existent in… | COVID-19 / pandemic |
| NCT05896163 | A Study to Learn About the Effects of Two Study Medicines (Maplirpacept [PF-07901801] And…(MAPtivate-6) | Phase 1 / Phase 2 | terminated | Jun 9, 2023 | Pfizer | Business/Administrative decision to pursue other programs/assets within the oncology portfolio. Not… | Safety / toxicity |
| NCT07453446 | Clinical Study of U29 Injection (CD30-CART) in Patients With CD30-Positive… | Phase 1 | withdrawn | Mar 6, 2026 | Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd | The main consideration is the allocation of company resources, We can only terminate this research. | Sponsor / business decision |
| NCT03506373 | Ibrutinib and Ixazomib Citrate in Treating Newly Diagnosed, Relapsed or Refractory… | Phase 2 | terminated | Apr 24, 2018 | Mayo Clinic | Discontinued after interim analysis for futility; no treatment successes observed in the first 12… | Efficacy / futility |
| NCT03173092 | A Study of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD)… | Phase 4 | terminated | Jun 1, 2017 | Takeda | All participants on the study have concluded treatment, core study activities are complete, and the… | Other (stated, no rule matched) |
| NCT05337735 | A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare… | Phase 2 | suspended | Apr 20, 2022 | M.D. Anderson Cancer Center | PI Request | Other (stated, no rule matched) |
| NCT05846737 | BCMA CAR-T Cell Therapy in High-risk NDMM Patients With Positive MRD After First-line ASCT | Phase 2 | withdrawn | May 6, 2023 | Institute of Hematology & Blood Diseases Hospital, China | The study was withdrawn due to the inability to enroll participants. | Enrollment / accrual |
| NCT06769555 | BCMA/CD3 BiTE for RRAL or NDAL Amyloidosis With Insufficient Depth of Hematologic… | N/A | withdrawn | Jan 10, 2025 | Institute of Hematology & Blood Diseases Hospital, China | The study protocol was withdrawn because, after modifications, the study transitioned from an… | Investigator |
| NCT07282548 | Study of Tazemetostat in Adults With Follicular Lymphoma Previously Treated With at Least… | — | withdrawn | Dec 15, 2025 | Ipsen | Withdrawn prior to enrolment after review of updated safety data | Safety / toxicity |
| NCT06125028 | [68Ga]Ga-PentixaFor-PET Imaging for Staging of Marginal Zone Lymphoma(LYMFOR) | Phase 3 | terminated | Nov 9, 2023 | Pentixapharm AG | low recruitment rate | Enrollment / accrual |
| NCT03622775 | Daratumumab in Treating Participants With Relapsed Multiple Myeloma After Stem Cell… | Phase 2 | terminated | Aug 9, 2018 | M.D. Anderson Cancer Center | \<75% participation | Other (stated, no rule matched) |
| NCT05090566 | MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer… | Phase 2 | terminated | Oct 25, 2021 | Pfizer | A business decision was made by Pfizer to terminate the study and not proceed with the Phase 2… | Safety / toxicity |
| NCT06163898 | A Study to Evaluate Alnuctamab in Combination With Mezigdomide in Participants With… | Phase 1 | terminated | Dec 11, 2023 | Celgene | Business objectives have changed | Sponsor / business decision |
| NCT05605119 | First in Human, Dose Escalation, Dose Expansion Study of AUR105(SURYA-1) | Phase 1 | terminated | Nov 4, 2022 | Aurigene Discovery Technologies Limited | Patient recruitment problems. | Enrollment / accrual |
| NCT05607199 | A First in Human Study of AUR 103 Calcium to Evaluate Safety, Pharmacokinetics and…(BHARAT-1) | Phase 1 | terminated | Nov 7, 2022 | Aurigene Discovery Technologies Limited | Patient recruitment problems. | Enrollment / accrual |
| NCT05983965 | Study of Tazemetostat in Lymphoid Malignancies | Phase 1 | terminated | Aug 9, 2023 | University of Alabama at Birmingham | Ipsen, drug company requested all studies using the drug Taxemetostat be terminated due to… | Sponsor / business decision |
| NCT05498220 | Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma | Phase 2 | terminated | Aug 11, 2022 | UNC Lineberger Comprehensive Cancer Center | Funding | Funding |
| NCT03856216 | Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma… | Phase 2 | terminated | Feb 27, 2019 | M.D. Anderson Cancer Center | \<75% participation | Other (stated, no rule matched) |
| NCT06088654 | Phase1/2 Study of IPH6501 in Patients With Relapsed /Refractory B-Cell Non-Hodgkin… | Phase 1 / Phase 2 | terminated | Oct 18, 2023 | Innate Pharma | Following Completion of dose escalation, the study has been discontinued as part of the Company's… | Sponsor / business decision |
| NCT01081028 | Connect® MM- The Multiple Myeloma Disease Registry | — | terminated | Mar 5, 2010 | Celgene | Business objectives have changed | Sponsor / business decision |
| NCT06767956 | Golcadomide and Nivolumab in Patients With Non-Hodgkin Lymphoma With Refractory Disease… | Phase 1 / Phase 2 | withdrawn | Jan 10, 2025 | University of Pittsburgh | IND Sponsor-Investigator left institution | Investigator |
| NCT04853329 | Dose Escalation and Expansion Study of CPO107 for Patients With Advanced CD20-positive… | Phase 1 | terminated | Apr 21, 2021 | Conjupro Biotherapeutics, Inc. | Business reasons | Sponsor / business decision |
| NCT07030699 | A Study of Epcoritamab With Lenalidomide and Tafasitamab in People With Diffuse Large B…(ECLAT) | Phase 2 | withdrawn | Jun 22, 2025 | Memorial Sloan Kettering Cancer Center | Lack of accrual | Enrollment / accrual |
| NCT02681302 | Check Point Inhibition After Autologous Stem Cell Transplantation in Patients at High…(CPIT001) | Phase 1 / Phase 2 | terminated | Feb 12, 2016 | Hackensack Meridian Health | Lack of Accrual | Enrollment / accrual |
| NCT05618366 | Tazemetostat and Venetoclax in Relapsed/Refractory Non-Hodgkin Lymphoma | Phase 1 | terminated | Nov 16, 2022 | Weill Medical College of Cornell University | Low accrual | Enrollment / accrual |
| NCT04903197 | Study of VAY736 as Single Agent and in Combination With Select Antineoplastic Agents in… | Phase 1 | terminated | May 26, 2021 | Novartis Pharmaceuticals | Business decision and not due to any safety or tolerability concerns. | Safety / toxicity |
| NCT06692452 | Tazemetostat Plus CHOP in 1L T-cell Lymphoma | Phase 2 | withdrawn | Nov 18, 2024 | Eric Jacobsen, MD | Ipsen requested a temporary closure due to a safety concern. | Safety / toxicity |
| NCT07049432 | N-803 Maintenance Therapy Post CAR T-cell Therapy in Patients With Relapsed or Refractory…(CARMEN-803) | Phase 1 | withdrawn | Jul 3, 2025 | University of Utah | Drug Unavailable | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated Jun 10, 2026source: clinicaltrials